New COVID-19 vaccine shows promise in early human trial
NCT ID NCT05408312
First seen Jan 20, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This early-stage study tested a new COVID-19 vaccine (GEN2) in 234 healthy adults aged 18 and older. The main goal was to check if the vaccine is safe and how well it triggers an immune response. Participants received one of three vaccine doses or a placebo, and researchers monitored side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 PNEUMONIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
Conditions
Explore the condition pages connected to this study.